Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 7, 2014; 20(37): 13234-13238
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13234
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13234
Biological therapy for ulcerative colitis: An update
Geom Seog Seo, Department of Gastroenterology, Wonkwang University School of Medicine, Digestive Disease Research Institute, Chonbuk 570-749, South Korea
Soo-Cheon Chae, Department of Pathology, Wonkwang University School of Medicine, Digestive Disease Research Institute, Chonbuk 570-749, South Korea
Author contributions: Seo GS wrote the first draft of the paper; Chae SC revised the manuscript.
Supported by Grants from Wonkwang University in 2013
Correspondence to: Soo-Cheon Chae, PhD, Professor, Department of Pathology, Wonkwang University School of Medicine, Digestive Disease Research Institute, 460 Iksandae-ro, Iksan, Cheonbuk 570-749, South Korea. chaesc@wonkwang.ac.kr
Telephone: +82-63-8506793 Fax: +82-63-8522110
Received: February 28, 2014
Revised: June 16, 2014
Accepted: July 22, 2014
Published online: October 7, 2014
Revised: June 16, 2014
Accepted: July 22, 2014
Published online: October 7, 2014
Core Tip
Core tip: In the last two years, the use of the Janus kinase 3 inhibitor (oral tofacitinib) and the α4β7 integrin blocker (vedolizumab) reportedly achieved good clinical response and remission rates in ulcerative colitis patients. Thus, we believe that the detailed investigation of various studies on clinical trials performed thus far may provide important information for the selection of appropriate biological agents, and therefore, we have extensively reviewed such trials in the present study.